Vanguard Group’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $109M | Buy |
4,027,407
+72,817
| +2% | +$1.92M | ﹤0.01% | 1837 |
|
|
2025
Q3 | $102M | Sell |
3,954,590
-2,532
| -0.1% | -$58.7K | ﹤0.01% | 1854 |
|
|
2025
Q2 | $80.5M | Buy |
3,957,122
+58,687
| +2% | +$1.14M | ﹤0.01% | 1920 |
|
|
2025
Q1 | $70.8M | Buy |
3,898,435
+16,440
| +0.4% | +$367K | ﹤0.01% | 1945 |
|
|
2024
Q4 | $98.1M | Buy |
3,881,995
+12,213
| +0.3% | +$332K | ﹤0.01% | 1876 |
|
|
2024
Q3 | $132M | Buy |
3,869,782
+130,743
| +3% | +$4.98M | ﹤0.01% | 1749 |
|
|
2024
Q2 | $138M | Buy |
3,739,039
+88,457
| +2% | +$3.34M | ﹤0.01% | 1694 |
|
|
2024
Q1 | $153M | Buy |
3,650,582
+604,251
| +20% | +$24.8M | ﹤0.01% | 1661 |
|
|
2023
Q4 | $121M | Buy |
3,046,331
+427,827
| +16% | +$12.6M | ﹤0.01% | 1760 |
|
|
2023
Q3 | $72.1M | Buy |
2,618,504
+20,688
| +0.8% | +$648K | ﹤0.01% | 1966 |
|
|
2023
Q2 | $88.1M | Buy |
2,597,816
+49,218
| +2% | +$1.66M | ﹤0.01% | 1920 |
|
|
2023
Q1 | $91.7M | Buy |
2,548,598
+35,034
| +1% | +$1.51M | ﹤0.01% | 1869 |
|
|
2022
Q4 | $112M | Buy |
2,513,564
+38,183
| +2% | +$1.36M | ﹤0.01% | 1748 |
|
|
2022
Q3 | $69.6M | Buy |
2,475,381
+40,009
| +2% | +$1.23M | ﹤0.01% | 2008 |
|
|
2022
Q2 | $65.7M | Buy |
2,435,372
+1,777
| +0.1% | +$51.6K | ﹤0.01% | 2064 |
|
|
2022
Q1 | $82.9M | Buy |
2,433,595
+20,539
| +0.9% | +$657K | ﹤0.01% | 2052 |
|
|
2021
Q4 | $93.2M | Buy |
2,413,056
+136,857
| +6% | +$5.96M | ﹤0.01% | 2019 |
|
|
2021
Q3 | $123M | Buy |
2,276,199
+305,793
| +16% | +$14.3M | ﹤0.01% | 1868 |
|
|
2021
Q2 | $65.9M | Buy |
1,970,406
+172,079
| +10% | +$4.72M | ﹤0.01% | 2222 |
|
|
2021
Q1 | $37M | Buy |
1,798,327
+30,412
| +2% | +$698K | ﹤0.01% | 2470 |
|
|
2020
Q4 | $31M | Buy |
1,767,915
+44,598
| +3% | +$803K | ﹤0.01% | 2428 |
|
|
2020
Q3 | $25.6M | Buy |
1,723,317
+427,111
| +33% | +$5M | ﹤0.01% | 2333 |
|
|
2020
Q2 | $16.9M | Buy |
1,296,206
+758,278
| +141% | +$3.36M | ﹤0.01% | 2506 |
|
|
2020
Q1 | $893K | Buy |
537,928
+21,810
| +4% | +$49.3K | ﹤0.01% | 3518 |
|
|
2019
Q4 | $1.15M | Hold |
516,118
| – | – | ﹤0.01% | 3602 |
|
|
2019
Q3 | $1.1M | Buy |
516,118
+217,444
| +73% | +$503K | ﹤0.01% | 3627 |
|
|
2019
Q2 | $800K | Sell |
298,674
-189,562
| -39% | -$644K | ﹤0.01% | 3735 |
|
|
2019
Q1 | $2.4M | Buy |
488,236
+70,776
| +17% | +$372K | ﹤0.01% | 3388 |
|
|
2018
Q4 | $1.24M | Buy |
417,460
+14,289
| +4% | +$70.2K | ﹤0.01% | 3500 |
|
|
2018
Q3 | $2.73M | Buy |
403,171
+28,113
| +7% | +$197K | ﹤0.01% | 3432 |
|
|
2018
Q2 | $2.83M | Sell |
375,058
-25,474
| -6% | -$341K | ﹤0.01% | 3396 |
|
|
2018
Q1 | $14M | Sell |
400,532
-168,680
| -30% | -$6.54M | ﹤0.01% | 2649 |
|
|
2017
Q4 | $24.2M | Buy |
569,212
+57,773
| +11% | +$2.47M | ﹤0.01% | 2417 |
|
|
2017
Q3 | $21.9M | Sell |
511,439
-140,218
| -22% | -$5.26M | ﹤0.01% | 2453 |
|
|
2017
Q2 | $24.1M | Buy |
651,657
+47,206
| +8% | +$2.09M | ﹤0.01% | 2377 |
|
|
2017
Q1 | $32.7M | Buy |
604,451
+85,214
| +16% | +$4.44M | ﹤0.01% | 2192 |
|
|
2016
Q4 | $27.6M | Buy |
519,237
+20,045
| +4% | +$1.14M | ﹤0.01% | 2259 |
|
|
2016
Q3 | $30.3M | Buy |
499,192
+14,969
| +3% | +$932K | ﹤0.01% | 2171 |
|
|
2016
Q2 | $31.9M | Buy |
484,223
+32,807
| +7% | +$2.08M | ﹤0.01% | 2112 |
|
|
2016
Q1 | $25.6M | Sell |
451,416
-1,336
| -0.3% | -$150K | ﹤0.01% | 2183 |
|
|
2015
Q4 | $106M | Buy |
452,752
+14,583
| +3% | +$3.18M | 0.01% | 1423 |
|
|
2015
Q3 | $69.3M | Buy |
438,169
+14,253
| +3% | +$4.03M | 0.01% | 1692 |
|
|
2015
Q2 | $160M | Buy |
423,916
+17,876
| +4% | +$7.1M | 0.01% | 1213 |
|
|
2015
Q1 | $170M | Buy |
406,040
+45,683
| +13% | +$16.3M | 0.01% | 1126 |
|
|
2014
Q4 | $98.6M | Buy |
360,357
+13,561
| +4% | +$3.37M | 0.01% | 1425 |
|
|
2014
Q3 | $67.4M | Buy |
346,796
+1,491
| +0.4% | +$325K | 0.01% | 1629 |
|
|
2014
Q2 | $84.5M | Buy |
345,305
+6,432
| +2% | +$1.45M | 0.01% | 1512 |
|
|
2014
Q1 | $89.8M | Buy |
338,873
+7,388
| +2% | +$2.83M | 0.01% | 1420 |
|
|
2013
Q4 | $120M | Buy |
331,485
+76,865
| +30% | +$29.6M | 0.01% | 1198 |
|
|
2013
Q3 | $135M | Buy |
254,620
+86,760
| +52% | +$29.7M | 0.01% | 1052 |
|
|
2013
Q2 | $39.3M | Buy |
+167,860
| New | +$33.1M | ﹤0.01% | 1778 |
|
Other funds holding CLDX
KCM
BG
CC
DTC
B
Vanguard Group's CLDX Position: Q4 2025 in Review
Vanguard Group increased its Celldex Therapeutics (CLDX) stake by 1.8% in Q4 2025, buying an estimated $1.92M and bringing the position to 4,027,407 shares worth $109M. The position accounts for ﹤0.01% of the portfolio, ranked #1837.
Vanguard Group first reported a position in CLDX in Q2 2013 and has held it in 51 quarters since. The position peaked at $170M in Q1 2015. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.
- Vanguard Group held 4,027,407 shares of Celldex Therapeutics worth $109M as of Q4 2025.
- Vanguard Group bought 72,817 Celldex Therapeutics shares in Q4 2025, an estimated $1.92M.
- Celldex Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1837 holding.
- Vanguard Group first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Celldex Therapeutics position peaked at $170M in Q1 2015.
- 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.